Tumour necrosis factor-α and myoglobin associated with the recovery time of coronary artery lesions in Kawasaki disease patients.


Journal

Journal of paediatrics and child health
ISSN: 1440-1754
Titre abrégé: J Paediatr Child Health
Pays: Australia
ID NLM: 9005421

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 14 12 2018
revised: 20 01 2020
accepted: 12 04 2020
pubmed: 2 6 2020
medline: 15 5 2021
entrez: 2 6 2020
Statut: ppublish

Résumé

To assess the relationship between clinical parameters and medium term recovery time of coronary artery lesions (CALs). In total, 344 Kawasaki disease patients were screened and 311 Kawasaki disease patients were included and followed-up for the next 2 years. Clinical records, clinical parameters and inflammatory biomarkers were collected for all subjects. Tumour necrosis factor (TNF)-α and myoglobin (MYO) levels in patients without recovery from CALs were significantly higher than those without CALs and with recovery from CALs. Kaplan-Meier survival analysis showed that in the high-TNF-α group, the estimated median time to recovery (5.0 months, 95% confidence interval (CI) 1.436-8.564) is significantly longer than the low-TNF-α group (2.00 months, 95% CI: 0.633-3.367, P = 0.044). Also, the estimated median time (5.0 months, 95% CI: 1.836-8.164) in the high-MYO group is significantly longer than the low-MYO group (2.00 months, 95% CI: 0.405-3.595, P = 0.002). Cox regression analysis showed independent factors for recovery of CALs included age, left coronary artery to aortic annulus ratio, TNF-α and MYO levels. These findings suggest that clinical parameters such as age, left coronary artery to aortic annulus ratio, TNF-α and MYO levels associate with medium term recovery time of CALs and could help in the design of a clinical strategy for the surveillance and prevention of late cardiovascular events.

Identifiants

pubmed: 32479688
doi: 10.1111/jpc.14942
doi:

Substances chimiques

Myoglobin 0
Tumor Necrosis Factor-alpha 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1382-1387

Subventions

Organisme : China National Natural Science Fund
ID : 81600502
Organisme : Clinical Guidance Project of Hunan Provincial Science and Technology Department
ID : 2017SK50502
Organisme : The Young Doctor Training Program
ID : BSJJ201801

Informations de copyright

© 2020 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).

Références

Newburger JW, Takahashi M, Burns JC. Kawasaki disease. J. Am. Coll. Cardiol. 2016; 67: 1738-49.
Suda K, Iemura M, Nishiono H et al. Long-term prognosis of patients with Kawasaki disease complicated by giant coronary aneurysms: A single-institution experience. Circulation 2011; 123: 1836-42.
McCrindle BW, Harris KC. Coronary artery aneurysms after Kawasaki disease: Understanding the pathology. Can. J. Cardiol. 2018; 34: 1094-7.
McCrindle BW, Rowley AH, Newburger JW et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American Heart Association. Circulation 2017; 135: e927-99.
Newburger JW, Takahashi M, Gerber MA et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association. Circulation 2004; 110: 2747-71.
Li W, Zhang L, Huang P, Zhang Z. Clinical features and mid-term follow-up in infants younger than 3 months with Kawasaki disease in a Chinese population. J Paediatr Child Health 2019; 55(5): 523-7.
Burns JC, Hoshino S, Kobayashi T. Kawasaki disease: An essential comparison of coronary artery aneurysm criteria. Lancet Child Adolesc. Health 2018; 2: 840-1.
Bal AK, Prasad D, Umali Pamintuan MA, Mammen-Prasad E, Petrova A. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease. Pediatr. Neonatol. 2014; 55: 387-92.
Del Principe D, Pietraforte D, Gambardella L et al. Pathogenetic determinants in Kawasaki disease: The haematological point of view. J. Cell. Mol. Med. 2017; 21: 632-9.
Fu PP, Du ZD, Pan YS. Novel predictors of intravenous immunoglobulin resistance in Chinese children with Kawasaki disease. Pediatr. Infect. Dis. J. 2013; 32: e319-23.
Maric LS, Knezovic I, Papic N et al. Risk factors for coronary artery abnormalities in children with Kawasaki disease: A 10-year experience. Rheumatol. Int. 2015; 35: 1053-8.
Ram Krishna M, Sundaram B, Dhanalakshmi K. Predictors of coronary artery aneurysms in Kawasaki disease. Clin. Pediatr. 2014; 53: 561-5.
Okuma Y, Suda K, Nakaoka H et al. Serum Tenascin-C as a novel predictor for risk of coronary artery lesion and resistance to intravenous immunoglobulin in Kawasaki disease - A multicenter retrospective study. Circ. J. 2016; 80: 2376-81.
Hwang JY, Lee KY, Rhim JW et al. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease. Arch. Dis. Child. 2011; 96: 1088-90.
JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version. Circ. J. 2014; 78: 2521-62.
Dionne A, Ibrahim R, Gebhard C et al. Coronary wall structural changes in patients with Kawasaki disease: New insights from optical coherence tomography (OCT). J. Am. Heart Assoc. 2015; 4: e001939.
Guo MM, Tseng WN, Ko CH, Pan HM, Hsieh KS, Kuo HC. Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease. Allergy 2015; 70: 310-8.
Hu P, Jiang GM, Wu Y et al. TNF-alpha is superior to conventional inflammatory mediators in forecasting IVIG nonresponse and coronary arteritis in Chinese children with Kawasaki disease. Clin. Chim. Acta 2017; 471: 76-80.
Wang Y, Wang W, Gong F et al. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease. Arthritis Rheum. 2013; 65: 805-14.
Mitani Y, Sawada H, Hayakawa H et al. Elevated levels of high-sensitivity C-reactive protein and serum amyloid-A late after Kawasaki disease: Association between inflammation and late coronary sequelae in Kawasaki disease. Circulation 2005; 111: 38-43.
Hui-Yuen JS, Duong TT, Yeung RS. TNF-alpha is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J. Immunol. 2006; 176: 6294-301.
Zhang YQ, Chen SB, Huang GY et al. Coronary artery indexed diameter and z score regression equations in healthy Chinese Han children. J. Clin. Ultrasound 2015; 43: 39-46.
Na JH, Kim S, Eun LY. Utilization of coronary artery to aorta for the early detection of Kawasaki disease. Pediatr. Cardiol. 2018; 40: 461-7.

Auteurs

Chun Guo (C)

Children's Medical Center, Hunan Provincial People's Hospital, the First Affiliated Hospital, Hunan Normal University, Changsha, China.

Chaochao Tan (C)

Department of Clinical Laboratory, Hunan Provincial People's Hospital, the First Affiliated Hospital, Hunan Normal University, Changsha, China.

Xiaohui Xia (X)

Ultrasound Department, Hunan Provincial People's Hospital, the First Affiliated Hospital, Hunan Normal University, Changsha, China.

Yonghua Yuan (Y)

Children's Medical Center, Hunan Provincial People's Hospital, the First Affiliated Hospital, Hunan Normal University, Changsha, China.

Menghua Zhao (M)

Children's Medical Center, Hunan Provincial People's Hospital, the First Affiliated Hospital, Hunan Normal University, Changsha, China.

Zhijie Yuan (Z)

Children's Medical Center, Hunan Provincial People's Hospital, the First Affiliated Hospital, Hunan Normal University, Changsha, China.

Yupeng Wang (Y)

Department of Clinical Laboratory, Hunan Provincial People's Hospital, the First Affiliated Hospital, Hunan Normal University, Changsha, China.

Zhonghua Deng (Z)

Department of Clinical Laboratory, Hunan Provincial People's Hospital, the First Affiliated Hospital, Hunan Normal University, Changsha, China.

Jie Chen (J)

Department of Clinical Laboratory, Hunan Provincial People's Hospital, the First Affiliated Hospital, Hunan Normal University, Changsha, China.

Yujie Zhou (Y)

Department of Clinical Laboratory, Hunan Provincial People's Hospital, the First Affiliated Hospital, Hunan Normal University, Changsha, China.

Ying Huang (Y)

Department of Emergency, Hunan Provincial People's Hospital, the First Affiliated Hospital, Hunan Normal University, Changsha, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH